Guest guest Posted July 19, 2010 Report Share Posted July 19, 2010 Article lead-in reprinted from Aspergillus Online Newsletter, July 2010 Isavuconazole is a new antifungal which has excellent activity against Aspergillus and many other fungi. It is currently undergoing a phase III clinical trial, after which all being well and subject to approval the drug can be used in the clinic. Isavuconazole thus may well be one of the next new drug's to be used to treat aspergillosis and a review in an Aspergillus online newsletter comprehensively summarises its published data & looks at the potential advantages it may bring to the clinic. Isavuconazole is available as an oral drug so will be convenient to administer (unlike amphotericin and currently available echinocandins). It has a longer half life compared with azoles currently in use and toxicities similar to those found on other azoles e.g. phototoxicity are absent or undetected so far. Overall the toxicity profile is similar to that of fluconazole. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.